Genmab acquires Merus for $8bn, adding promising oncology asset petosemtamab. Check out my thoughts on this deal and my ratings on GMAB and MRUS stocks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback